Stevens Capital Management LP Raises Stake in Cencora, Inc. $COR

Stevens Capital Management LP boosted its position in shares of Cencora, Inc. (NYSE:COR) by 42.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,879 shares of the company’s stock after acquiring an additional 862 shares during the period. Stevens Capital Management LP’s holdings in Cencora were worth $863,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Private Advisor Group LLC lifted its position in shares of Cencora by 9.2% during the 1st quarter. Private Advisor Group LLC now owns 6,796 shares of the company’s stock worth $1,890,000 after purchasing an additional 572 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in Cencora in the first quarter valued at $753,000. Pinnacle Associates Ltd. lifted its holdings in Cencora by 67.9% during the 1st quarter. Pinnacle Associates Ltd. now owns 2,817 shares of the company’s stock worth $783,000 after buying an additional 1,139 shares during the last quarter. SFE Investment Counsel purchased a new stake in Cencora during the 1st quarter worth about $234,000. Finally, Advisor OS LLC boosted its holdings in Cencora by 28.4% in the first quarter. Advisor OS LLC now owns 2,881 shares of the company’s stock valued at $801,000 after purchasing an additional 638 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares in the company, valued at $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 46,640 shares of company stock worth $14,099,338 over the last three months. 10.80% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on COR shares. UBS Group raised their price objective on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, November 7th. TD Cowen raised their target price on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Robert W. Baird lifted their price target on Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Mizuho upped their target price on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Finally, JPMorgan Chase & Co. lifted their price target on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and a consensus price target of $371.09.

Cencora Trading Up 1.0%

NYSE COR opened at $365.56 on Friday. Cencora, Inc. has a 12 month low of $223.92 and a 12 month high of $369.38. The company has a 50-day moving average of $327.70 and a 200-day moving average of $304.57. The company has a market cap of $70.87 billion, a P/E ratio of 37.61, a P/E/G ratio of 1.56 and a beta of 0.63. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period in the prior year, the firm posted $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is 30.19%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.